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■ The patient disposition for this interim analysis is shown 
in Figure 2.
■ Demographic and baseline characteristics are shown in 
Table 2. 
Safety and Tolerability (continued)
■ The proportion of patients with reported and confirmed 
hypoglycaemia is listed in Table 3. 
■ The most frequent AEs by dose at 102 wks are listed in 
Table 4. 
■ SAXA + MET was not associated with an increase in 
AEs pertaining to infections, localized oedema, or 
cardiovascular AEs vs PBO + MET.
■ There was a numerically higher incidence of skin-related 
AEs in the SAXA + MET groups vs the PBO + MET 
group (15.6%, 13.6%, and 22.7% vs 11.2% for SAXA 
2.5, 5, and 10 mg + MET vs PBO + MET, respectively). 
– There were no AEs with the preferred term of 
angioedema or Stevens-Johnson syndrome.
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■ Study Design (CV181-014)
– Design: Randomised, double-blind, PBO-controlled, 
4-arm, parallel-group, international, multicentre trial 
(Figure 1).
– Population: Patients (aged 18-77 yrs) with T2D and 
inadequate glycaemic control (HbA1c ≥7.0% –
≤10.0%) on a stable dose of MET for ≥8 wks prior to 
screening and with fasting  C-peptide ≥1.0 ng/mL, 
BMI ≤40 kg/m2.
– Intervention: 743 eligible patients were randomised 
and treated with SAXA 2.5 mg, SAXA 5 mg, SAXA 
10 mg, or PBO in addition to their current dose of 
open-label MET for 24 wks (ST treatment period). 
■ Diabetes is Australia’s fastest growing chronic disease 
with approximately 890,000 patients currently diagnosed 
with diabetes.1 By 2031 it is predicted that 3.3 million 
Australians will have type 2 diabetes mellitus,2 thus 
increasing the demand for treatment. Saxagliptin (SAXA) 
is a potent selective DPP-4 inhibitor designed for 
extended inhibition of the DPP-4 enzyme. The long-term 
efficacy and safety of SAXA added to metformin were 
assessed in patients with T2D and inadequate glycaemic 
control (A1C ≥7.0% − ≤10.0%) on metformin alone. For 
the double-blind (DB) short-term (ST) treatment period 
743 patients (baseline [BL] A1C 8.0%) were randomized 
and treated 1:1:1:1 to SAXA 2.5, 5, 10 mg or placebo od + 
stable metformin dose (1500−2500mg/d) for 24 weeks. 
Patients who met pre-specified glycaemic rescue criteria 
during ST treatment period received open-label 
pioglitazone 15-45 mg + blinded study medication and 
entered the DB 42-month long-term extension (LTE). 
Patients completing ST treatment period without rescue 
were also eligible to enter the 42mo LTE; pioglitazone 
rescue therapy was also available during the LTE based 
on prespecified glycaemic criteria. 
■ At 102 weeks placebo-subtracted A1C changes from BL 
(n/N) were -0.62, -0.72, and -0.52 for SAXA 2.5, 5, and 
10mg, respectively. The proportion of patients (n/N) 
discontinued for lack of glycaemic control or rescued for 
meeting prespecified glycaemic criteria was lower for 
SAXA. SAXA + metformin was generally well tolerated; 
AE frequency was 89.6%, 78.0%, and 86.7% for SAXA 
2.5, 5, and 10 mg vs. 78.8% for placebo + metformin. 
Proportion of patients with hypoglycaemia events (all) was 
10.4%, 8.9%, and 11.0% for SAXA 2.5, 5, and 10mg vs. 
10.1% for placebo + metformin and confirmed 
hypoglycaemia was infrequent. 
■ In summary, in patients with T2D inadequately controlled 
on metformin alone SAXA added to metformin provided 
sustained clinically meaningful glycaemic improvements 
over 102 weeks vs. control and was generally well 
tolerated with no increase in hypoglycaemia or weight.
■ MET is considered standard first-line pharmacotherapy 
for T2D. 
■ MET reduces hepatic glucose production and improves 
insulin sensitivity; however, MET alone  is frequently 
insufficient to maintain glycaemic goals in the face of 
progressive β-cell failure and increasing insulin 
resistance. 
■ SAXA is a potent, selective DPP-4 inhibitor specifically 
designed for extended inhibition of the DPP-4 enzyme. 
■ The CV181-014 trial evaluated the efficacy and safety of 
SAXA in combination with MET as  add-on therapy in 
patients with T2D and inadequate glycaemic control on 
MET alone.3
METHODS
ABSTRACT METHODS (continued) RESULTS (continued)
■ In this interim analysis of patients with T2D inadequately 
controlled on MET alone, the overall profile  of AEs 
associated with extended dosing of saxagliptin added to 
MET for up to 2 years was consistent with that seen at 
24 weeks. 
■ Saxagliptin added to MET provided sustained clinically 
meaningful glycaemic improvements over 102 weeks vs 
PBO + MET and was generally well tolerated with no 





• Patients remained on the same treatment assigned 
in the ST treatment period throughout  the LTE. 
• Patients and study investigators remained blinded 
to study medication throughout the LTE. 
>7.0%Wks 89-193
HbA1c = glycated haemoglobin; LTE = long-term extension. 
>7.5%Wks 63, 76
>8.0%Wks 30, 37, 50
HbA1cLTE
MeasurementVisit
Table 1. LTE Rescue Criteria for Lack of Glycaemic Control
INTRODUCTION
■ LTE Study Objectives 
– Assess safety and tolerability of each dose of SAXA 
+ MET when administered for up to 48 mos. 
– Assess safety and tolerability of each dose of 
SAXA + MET and PIO when administered for up 
to 42 mos. 
– For each SAXA treatment group, assess the 
glycaemic parameters in the LTE. 
■ Statistical Analyses
– Efficacy analyses for continuous variables were 
performed using an ANCOVA model with treatment 
as an effect and baseline as the covariate, and with 
LOCF methodology. 
– Percentages of patients achieving target HbA1c at 
wks 24, 50, 76, and 102 (LOCF) were compared 
between each combination treatment group vs the 
respective monotherapy group using the exact 
95% CI on the difference between groups. 
– Efficacy analyses reflect data prior to rescue. 
– Safety analyses reflect data regardless of rescue.
Table 2.  Demographic and Baseline Characteristics of 




SAXA 5 mg 
+ MET
SAXA 10 
mg + MET PBO + MET
Characteristics n=192 n=191 n=181 n=179
Age (yrs)a 54.7 (10.1) 54.7 (9.6) 54.2 (10.1) 54.8 (10.2)
≥65 yrsb 33 (17.2) 32 (16.8) 26 (14.4) 26 (14.5)
Genderb
Male 83 (43.2) 103 (53.9) 95 (52.5) 96 (53.6)
Female 109 (56.8) 88 (46.1) 86 (47.5) 83 (46.4)
Raceb
Caucasian 153 (79.7) 159 (83.2) 144 (79.6) 150 (83.8)
Black/African 
American 8 (4.2) 11 (5.8) 14 (7.7) 7 (3.9)
Asian 8 (4.2) 3 (1.6) 5 (2.8) 4 (2.2)
Other 23 (12.0) 18 (9.4) 18 (9.9) 18 (10.1)
Body weight (kg)a 86.0 (17.6) 87.3 (17.0) 87.8 (18.9) 87.1 (17.8)
BMI (kg/m2)a 31.7 (5.2) 31.2 (4.7) 31.1 (4.8) 31.6 (4.8)
Diabetes duration 
(yrs)a 6.7 (5.6) 6.4 (4.7) 6.3 (4.4) 6.7 (5.6)
HbA1c (%)a 8.1 (1.0) 8.1 (0.8) 8.0 (1.0) 8.1 (0.9)
FPG (mg/dL)a 174 (44.3) 180 (47.7) 176 (50.2) 174 (43.5)
Table 3.  Safety and Tolerability During ST + LTE Treatment 
Period by Treatment Group
SAXA 2.5 
mg + MET
SAXA 5 mg 
+ MET
SAXA 10 mg 
+ MET PBO + MET
n=192 n=191 n=181 n=179
Exposure (weeks)a,b 78 (32.3) 75 (34.1) 81 (31.1) 68 (35.3)
AEsc
≥1 AE 172 (89.6) 149 (78.0) 157 (86.7) 141 (78.8)
≥1 related AE 50 (26.0) 56 (29.3) 61 (33.7) 50 (27.9)
Deaths 0 0 1 (0.6) 2 (1.1)
≥1 SAE 17 (8.9) 19 (9.9) 20 (11.0) 10 (5.6)
≥1 related  SAE 0 1 (0.5) 1 (0.6) 0
Discontinuation due 
to AE 9 (4.7) 14 (7.3) 10 (5.5) 8 (4.5)
Discontinuation due 
to SAEs 3 (1.6) 3 (1.6) 5 (2.8) 0
Reported   
hypoglycaemiac,d 20 (10.4) 17 (8.9) 20 (11.0) 18 (10.1)
Confirmed 
hypoglycaemiac,e 2 (1.0) 2 (1.0) 2 (1.1) 1 (0.6)
a Exposure = Last dosing date (ST + LTE double-blind treatment) − first dosing (ST 
period) + 1.
b Values are expressed as mean (SD).
c Values are expressed as n (%).
d Reported hypoglycaemia was defined as events consistent with signs or symptoms of 
hypoglycaemia with or without documented blood glucose levels. 
e Confirmed hypoglycaemia was defined by a fingerstick glucose value
≤50 mg/dL with associated symptoms.
aValues are expressed as mean (SD). bValues are expressed as n (%). 
BMI = body mass index; FPG = fasting plasma glucose.
Table 4. Most Frequent AEs by Dose for Each SAXA 
Treatment Group vs PBO at 102 Wks
AEa SAXA 2.5 mg + MET
SAXA 5 mg 
+ MET




n=192 n=191 n=181 n=179
Nasopharyngitis 25 (13.0) 21 (11.0) 25 (13.8) 19 (10.6)
Influenza 20 (10.4) 22 (11.5) 23 (12.7) 23 (12.8)
URTI 23 (12.0) 17 (8.9) 19 (10.5) 14 (7.8)
UTI 19 (9.9) 15 (7.9) 17 (9.4) 12 (6.7)
Bronchitis 12 (6.3) 18 (9.4) 9 (5.0) 11 (6.1)
diarrhoea 27 (14.1) 14 (7.3) 17 (9.4) 12 (12.8)
Back Pain 15 (7.8) 15 (7.9) 9 (5.0) 16 (8.9)
Headache 26 (13.5) 17 (8.9) 22 (12.2) 20 (11.2)
aValues are expressed as n (%). 
Five most frequent AEs by dose highlighted in purple.
URTI = upper respiratory tract infection; UTI = urinary tract infection. 
■ There was a decrease in the mean absolute 
lymphocyte count from baseline to wk 102 of  small 
magnitude in all treatment groups including PBO with 
the maximal reduction seen in  the SAXA 10 mg 
group. 
– There was no progressive decline in mean 
absolute lymphocyte count and values remained 
within the normal range in all treatment groups 
throughout the ST + LTE periods.
■ There were no clinically meaningful drug effects on 
any laboratory safety parameter.
Efficacy
■ More patients treated with PBO + MET were 
discontinued or rescued for lack of glycaemic control; 
rescue for meeting prespecified glycaemic criteria 
occurred earlier in the study in the PBO + MET group 
(Figure 3). 
■ SAXA was associated with greater reductions in 
HbA1c in all treatment groups vs PBO through wk 102 
(Figure 4). 
– The greatest HbA1c reduction was in the SAXA 
5 mg group. 
■ SAXA added to MET produced sustained effects up to 
wk 102 in the wk 24 secondary end points relative to 
control (Table 5). 
■ Small decreases in mean body weight at wk 102 
(before rescue, LOCF) vs baseline were  observed in 
all treatment groups. 
– At wk 102, mean change from baseline was -1.0, -
0.4, and -0.5 kg for SAXA 2.5, 5, and 10 mg + 
MET, respectively, vs -0.8 kg for the PBO + 
MET group.
STUDY LIMITATIONS
– LTE Entry (2 Routes):   
•Patients completing the ST treatment period without 
rescue therapy:   
– PIO rescue therapy available during the LTE 
based on prespecified glycaemic criteria (Table 1). 
•Patients who met prespecified glycaemic rescue 
criteria during the ST treatment period:   
– Open-label PIO 15 mg to 45 mg + blinded study 
medication. 
Safety and Tolerability
■ SAXA + MET was generally well tolerated (Table 3). The 
proportion of patients experiencing AEs was numerically 
higher in the SAXA + MET groups vs PBO + MET. 
– The higher incidence of AEs in the SAXA + MET 
groups needs to be interpreted in relation to the 
longer duration of exposure to study medication in 
patients randomised to SAXA + MET vs PBO + MET 
(Table 3).   
– No dose-related trends were observed. 
– There were 3 deaths reported, 1 in the SAXA 10 mg 
group (pulmonary embolism and lung neoplasm) 
and 2 in the PBO group (congestive heart failure; 
cardiogenic shock and MI).   
aPatient disposition at time of database lock for interim analysis (January 17, 2008). 
Rescued patients include all patients who were rescued in the ST or LTE. Rescued 
patients may later have discontinued from the study. 
Pts = patients; SAXA = saxagliptin; DC = total number of patients who discontinued from 
the study.
Total pts in study arm = total number in study at database lock for the interim analysis. 
Figure 2. Patient Dispositiona
Figure 1. Study Designa,b
a The current report describes interim analysis at time of database lock (January 17, 2008).
b Total duration of ST treatment period + LTE = 48 mos.
c If rescue criteria met in ST treatment period, added PIO and entered LTE phase; 
PIO rescue also available in LTE.
LTE = long-term extension; MET = metformin; o.d. = once daily; PIO = pioglitazone;
SAXA = saxagliptin; ST = short term.
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SAXA 2.5 mg 
+ MET
SAXA 5 mg + 
MET




n=192 n=191 n=181 n=179
HbA1c (%)
n observed 34 31 33 15
n for LOCF 181 184 177 172
Baseline 
mean (SE) 8.1 (0.07) 8.1 (0.06) 8.0 (0.08) 8.1 (0.07)
Adj mean ∆
from baseline -0.30 -0.40 -0.20 0.32
Diff vs PBO 
+ MET -0.62 -0.72 -0.52
95% CI (-0.84, -0.40) (-0.94, -0.50) (-0.74, -0.30)
FPG (mg/dL)
n observed 32 31 33 15
n for LOCF 183 184 178 173
Baseline 
mean (SE) 174 (3.3) 179 (3.5) 176 (3.8) 175 (3.3)
Adj mean ∆
from baseline -7.7 -11.3 -7.8 6.8
Diff vs PBO 
+ MET -14.6 -18.2 -14.6
95% CI (-22.7, -6.4) (-26.3, -10.0) (-22.8, -6.4)
HbA1c <7%,
n/N (%) 44/181 (24.3) 56/184 (30.4) 58/177 (32.8) 20/172 (11.6)
Diff vs PBO 
+ MET 12.7% 18.8% 21.1%
95% CI (4.7%, 20.7%) (10.4%, 27.1%) (12.6%, 29.6%)
Figure 3. Kaplan-Meier Curve for Discontinuation for Lack 
of Glycaemic Control or  Rescue for Failing to 
Achieve Glycaemic Targets During ST + LTE 
Treatment Period
Figure 4. HbA1C Mean Values (LOCF) During ST + LTE 
Treatment Period
1 = SAXA 2.5 mg + MET; 2 = SAXA 5 mg + MET; 3 = SAXA 10 mg + MET; 4 = PBO + MET.
■ There was a decreasing number of patients with pre-rescue 
HbA1c measurements observed at later time points. 
■ For the interim analysis, only patients who received the first 
dose of study drug early enough to have the potential to 
reach a specific time point were included in the LOCF 
analysis for that time point. 
■ Because glycaemic parameters would be affected by the 
addition of rescue therapy, efficacy results obtained after the 
initiation of rescue treatment were not included in any 
efficacy analyses. 
